# A Phase 1, Open-Label, 10 Day Safety Study

> **NCT01623401** · PHASE1 · COMPLETED · sponsor: **Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 72 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** TR-701 FA

## Key facts

- **NCT ID:** NCT01623401
- **Lead sponsor:** Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-17
- **Primary completion:** 2012-08-24
- **Final completion:** 2012-08-24
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623401, "A Phase 1, Open-Label, 10 Day Safety Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01623401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*